Sialic Acid-Siglec Axis in Human Immune Regulation, Involvement in Autoimmunity and Cancer and Potential Therapeutic Treatments
Open Access
- 28 May 2021
- journal article
- review article
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 22 (11) , 5774
Abstract
Siglecs are sialic acid-binding immunoglobulin-like lectins. Most Siglecs function as transmembrane receptors mainly expressed on blood cells in a cell type-specific manner. They recognize and bind sialic acids in specific linkages on glycoproteins and glycolipids. Since Sia is a self-molecule, Siglecs play a role in innate immune responses by distinguishing molecules as self or non-self. Increasing evidence supports the involvement of Siglecs in immune signaling representing immune checkpoints able to regulate immune responses in inflammatory diseases as well as cancer. Although further studies are necessary to fully understand the involvement of Siglecs in pathological conditions as well as their interactions with other immune regulators, the development of therapeutic approaches that exploit these molecules represents a tremendous opportunity for future treatments of several human diseases, as demonstrated by their application in several clinical trials. In the present review, we discuss the involvement of Siglecs in the regulation of immune responses, with particular focus on autoimmunity and cancer and the chance to target the sialic acid-Siglec axis as novel treatment strategy.Keywords
Funding Information
- Italian Ministry of Health (RC2020_INFETT_FIERABRACCI)
This publication has 130 references indexed in Scilit:
- In Silico-Aided Design of a Glycan Ligand of Sialoadhesin for in Vivo Targeting of MacrophagesJournal of the American Chemical Society, 2012
- Novel mechanism for the generation of human xeno-autoantibodies against the nonhuman sialic acid N-glycolylneuraminic acidJournal of Experimental Medicine, 2010
- Functionally defective germline variants of sialic acid acetylesterase in autoimmunityNature, 2010
- In vivo targeting of B-cell lymphoma with glycan ligands of CD22Blood, 2010
- Group B Streptococcus suppression of phagocyte functions by protein-mediated engagement of human Siglec-5Journal of Experimental Medicine, 2009
- Siglecs as targets for therapy in immune-cell-mediated diseaseTrends in Pharmacological Sciences, 2009
- CD24 and Siglec-10 Selectively Repress Tissue Damage–Induced Immune ResponsesScience, 2009
- Evidence for a human-specific mechanism for diet and antibody-mediated inflammation in carcinoma progressionProceedings of the National Academy of Sciences, 2008
- A unified vision of the building blocks of lifeNature Cell Biology, 2008
- Siglecs and their roles in the immune systemNature Reviews Immunology, 2007